Identification of a Novel Protective Human Monoclonal Antibody, LXY8, That Targets the Key Neutralizing Epitopes of Staphylococcal Enterotoxin B.

Naijing Hu,Chunxia Qiao,Jing Wang,Zhihong Wang,Xinying Li,Liuzhong Zhou,Jiaguo Wu,Dingmu Zhang,Jiannan Feng,Beifen Shen,Jinghai Zhang,Longlong Luo

DOI: https://doi.org/10.1016/j.bbrc.2021.02.057

IF: 3.1

2021-01-01

Biochemical and Biophysical Research Communications

Abstract:Staphylococcal enterotoxin B (SEB), one of the exotoxins produced by Staphylococcus aureus, is the key toxin that causes poisoning reactions and toxic shock syndrome. In the current research work, a novel human antibody named LXY8 was screened from a human phage display antibody library, and LXY8 blocked the interaction between SEB and the T cell receptor (TCR). The binding activity between LXY8 and SEB was 0.525 nM. Furthermore, LXY8 could effectively inhibit the SEB-induced activation of peripheral blood mononuclear cells and release of cytokines. In the BALB/c mouse model, LXY8 effectively neutralized SEB toxicity in vivo. Finally, based on computer-guided molecular modeling, we designed a series of SEB mutation sites; these sites facilitated the determination of the key residues (i.e. (EFNN179)-E-176) of SEB recognized by LXY8. The research revealed that the (EFNN179)-E-176 residues of SEB are important for specific antibody-antigen recognition. The results may be helpful for the development of antibody-based therapy for SEB-induced toxic shock syndrome. (C) 2021 Elsevier Inc. All rights reserved.